Anhedonia is a pathogenetically important clinical phenotype and a potential endophenotype for depressive symptoms with very high contributions from biological and genetic factors. The neurobiological mechanisms of anhedonia consist of impairments to the functioning of the brain “reward” system, which has been confirmed by a significant number of neuroimaging, genetic, and experimental studies. Anhedonia is transnosological in nature and is a complex phenomenon; its correct assessment in the context of one or another investigation paradigm is important. The optimum approach is to form a set of mutually supplementing investigation strategies assessing the most important facets of anhedonia, regardless of the relationship with the nosological form of the illness, in the framework of a single study using various methods to seek appropriate biomarkers for the severity of anhedonia (genetic, neuroimaging, biochemical). High-quality organization of studies of this type based on correct evidence-based medicine methodology should produce valuable systems of biomarkers in the near future, which when validated on independent cohorts will be useful for personalizing the diagnosis and treatment of depression.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
G. E. Mazo, G. V. Rukavishnikov, and A. O. Kibitov, “Therapeutic resistance in depression from the point of view of genetics and pharmacogenetics,” Obozr. Psikhiatr. Med. Psikhol., No. 4, Part 1, 43–47 (2019), https://doi.org/10.31363/2313-7053-2019-4-1-43-47.
M. Maes, B. Leonard, A. Fernandez, et al., “(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 35, No. 3, 659–663 (2011), https://doi.org/10.1016/j.pnpbp.2011.02.019.
P. F. Sullivan, M. C. Neale, and K. S. Kendler, “Genetic epidemiology of major depression: review and meta-analysis,” Am. J. Psychiatry, 157, No. 10, 1552–1562 (2000), https://doi.org/10.1176/appi.ajp.157.10.1552.
G. E. Mazo, N. G. Neznanov, and G. V. Rukavishnikov, “Psychiatric diagnosis: Up the down staircase,” Obozr. Psikhiatr. Med. Psikhol., 1, 15–24 (2015).
D. A. Pizzagalli, “Depression, stress, and anhedonia: toward a synthesis and integrated model,” Annu. Rev. Clin. Psychol., 10, 393–423 (2014), https://doi.org/10.1146/annurev-clinpsy-050212-185606.
M. T. Treadway, “The neurobiology of motivational deficits in depression – an update on candidate pathomechanisms,” Curr. Top. Behav. Neurosci., 27, 337–355 (2016), https://doi.org/10.1007/7854_2015_400.
S. H. Kennedy, “Core symptoms of major depressive disorder: relevance to diagnosis and treatment,” Dialogues Clin. Neurosci., 10, No. 3, 271–277 (2008), https://doi.org/10.31887/DCNS.2008.10.3/shkennedy.
A. Liao, R. Walker, T. J. Carmody, et al., “Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control,” J. Affect. Disord., 245, 1070–1078 (2019), https://doi.org/10.1016/j.jad.2018.11.072.
D. L. McMakin, T. M. Olino, G. Porta, et al., “Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression,” J. Am. Acad. Child Adolesc. Psychiatry, 51, No. 4, 404–411 (2012), https://doi.org/10.1016/j.jaac.2012.01.011.
G. E. Mazo and A. O. Kibitov, Anhedonia as a basic syndrome and a target for treatment in depressive disorder,” Obozr. Psikhiatr. Med. Psikhol., 3, 10–18 (2019), https://doi.org/10.31363/2313-7053-2019-3-10-18.
K. Gao, J. Sweet, M. Su, and J. R. Calabrese, “Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample,” Asian J. Psychiatr., 27, 40–47 (2017), https://doi.org/10.1016/j.ajp.2017.02.013.
F. Vinckier, D. Gourion, and S. Mouchabac, “Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners,” Eur. Psychiatry, 44, 1–8 (2017), https://doi.org/10.1016/j.eurpsy.2017.02.485.
G. D. Schrader, “Does anhedonia correlate with depression severity in chronic depression,” Compr. Psychiatry, 38, No. 5, 260–263 (1997), https://doi.org/10.1016/s0010-440x(97)90057-2.
F. M. Bos, F. J. Blaauw, E. Snippe, et al., “Exploring the emotional dynamics of subclinically depressed individuals with and without anhedonia: An experience sampling study,” J. Affect. Disord., 228, 186–193 (2018), https://doi.org/10.1016/j.jad.2017.12.017.
L. Pelizza and A. Ferrari, “Anhedonia in schizophrenia and major depression: state or trait,” Ann. Gen. Psychiatry, 8, 22 (2009), https://doi.org/10.1186/1744-859X-8-22.
P. O. Harvey, J. Pruessner, Y. Czechowska, and M. Lepage, “Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects,” Mol. Psychiatry, 12, No. 8, 767–775 (2007), https://doi.org/10.1038/sj.mp.4002021.
E. Barkus and J. C. Badcock, “A transdiagnostic perspective on social anhedonia,” Front. Psychiatry, 10, 216 (2019), https://doi.org/10.3389/fpsyt.2019.00216.
R. Coccurello, “Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing,” Behav. Brain Res., 372, 112041 (2019), https://doi.org/10.1016/j.bbr.2019.112041.
M. L. Cléry-Melin, F. Jollant, and P. Gorwood, “Reward systems and cognitions in Major Depressive Disorder,” CNS Spectr., 24, No. 1, 64–77 (2019), https://doi.org/10.1017/S1092852918001335.
C. Lambert, S. Da Silva, A. K. Ceniti, et al., “Anhedonia in depression and schizophrenia: A transdiagnostic challenge,” CNS Neurosci. Ther., 24, No. 7, 615–623 (2018), https://doi.org/10.1111/cns.12854.
P. Gorwood, “Neurobiological mechanisms of anhedonia,” Dial. Clin. Neurosci., 10, No. 3, 291–299 (2008), https://doi.org/10.31887/DCNS.2008.10.3/pgorwood.
M. E. Fox and M. K. Lobo, “The molecular and cellular mechanisms of depression: a focus on reward circuitry,” Mol. Psychiatry, 24, No. 12, 1798–1815 (2019), https://doi.org/10.1038/s41380-019-0415-3.
V. E. Heininga, E. Dejonckheere, M. Houben, et al., “The dynamical signature of anhedonia in major depressive disorder: positive emotion dynamics, reactivity, and recovery,” BMC Psychiatry, 19, No. 1, 59 (2019), https://doi.org/10.1186/s12888-018-1983-5.
L. Yin, X. Xu, G. Chen, et al., “Inflammation and decreased functional connectivity in a widely-distributed network in depression: Centralized effects in the ventral medial prefrontal cortex,” Brain Behav. Immun., 80, 657–666 (2019), https://doi.org/10.1016/j.bbi.2019.05.011.
B. Le Foll and L. French, “Transcriptomic characterization of the human habenula highlights drug metabolism and the neuroimmune system,” Front. Neurosci., 12, 742 (2018), https://doi.org/10.3389/fnins.2018.00742.
D. J. Stein, “Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry,” CNS Spectr., 13, No. 7, 561–565 (2008), https://doi.org/10.1017/s1092852900016837.
S. J. Rizvi, C. Lambert, and S. Kennedy, “Presentation and neurobiology of anhedonia in mood disorders: commonalities and distinctions,” Curr. Psychiatry Rep., 20, No. 2, 13 (2018), https://doi.org/10.1007/s11920-018-0877-z.
J. A. Cooper, A. R. Arulpragasam, and M. T. Treadway, “Anhedonia in depression: biological mechanisms and computational models,” Curr. Opin. Behav. Sci., 22, 128–135 (2018), https://doi.org/10.1016/j.cobeha.2018.01.024.
G. S. Kranz, S. Kasper, and R. Lanzenberger, “Reward and the serotonergic system,” Neuroscience, 166, No. 4, 1023–1035 (2010), https://doi.org/10.1016/j.neuroscience.2010.01.036.
K. M. Tye, J. J. Mirzabekov, M. R. Warden, et al., “Dopamine neurons modulate neural encoding and expression of depression-related behavior,” Nature, 493, No. 7433, 537–541 (2013), https://doi.org/10.1038/nature11740.
C. Martin-Soelch, “Is depression associated with dysfunction of the central reward system,” Biochem. Soc. Trans., 37, Part 1, 313–317 (2009), https://doi.org/10.1042/BST0370313.
P. Belujon and A. A. Grace, “Dopamine system dysregulation in major depressive disorders,” Int. J. Neuropsychopharmacol., 20, No. 12, 1036–1046 (2017), https://doi.org/10.1093/ijnp/pyx056.
R. Nusslock and L. B. Alloy, “Reward processing and mood-related symptoms: An RDoC and translational neuroscience perspective,” J. Affect. Disord., 216, 3–16 (2017), https://doi.org/10.1016/j.jad.2017.02.001.
T. M. Olino, D. L. McMakin, and E. E. Forbes, “Toward an empirical multidimensional structure of anhedonia, reward sensitivity, and positive emotionality: an exploratory factor analytic study,” Assessment, 25, No. 6, 679–690 (2018), https://doi.org/10.1177/1073191116680291.
M. S. Gold, K. Blum, M. Febo, et al., “Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems,” Front. Biosci. (Schol. Ed.), 10, 309–325. https://doi.org/10.2741/s518 (2018).
J. L. Moreau, “Simulating the anhedonia symptom of depression in animals,” Dialogues Clin. Neurosci., 4, No. 4, 351–360 (2002), https://doi.org/10.31887/DCNS.2002.4.4/jlmoreau.
H. Anisman and K. Matheson, “Stress, depression, and anhedonia: caveats concerning animal models,” Neurosci. Biobehav. Rev., 29, No. 4–5, 525–546 (2005), https://doi.org/10.1016/j.neubiorev.2005.03.007.
M. Heshmati and S. J. Russo, “Anhedonia and the brain reward circuitry in depression,” Curr. Behav. Neurosci. Rep., 2, No. 3, 146–153 (2015), https://doi.org/10.1007/s40473-015-0044-3.
E. M. Anderson, D. Gomez, A. Caccamise, et al., “Chronic unpredictable stress promotes cell-specific plasticity in prefrontal cortex D1 and D2 pyramidal neurons,” Neurobiol. Stress, 10, 100152 (2019), https://doi.org/10.1016/j.ynstr.2019.100152.
A. E. Nikolishin, A. G. Gofman, and A. O. Kibitov, “Alcohol dependence and depression: dopamine neuromediation as the clue to the study of comorbidity,” Narkologiya, 15, No. 8, 80–87 (2016).
G. Yadid and A. Friedman, “Dynamics of the dopaminergic system as a key component to the understanding of depression,” Prog. Brain Res., 172, 265–286 (2008), https://doi.org/10.1016/S0079-6123(08)00913-8.
M. G. Craske, A. E. Meuret, T. Ritz, et al., “Treatment for anhedonia: A neuroscience driven approach,” Depress. Anxiety, 33, No. 10, 927–938 (2016), https://doi.org/10.1002/da.22490.
G. R. Villas Boas, R. Boerngen de Lacerda, M. M. Paes, et al., “Molecular aspects of depression: A review from neurobiology to treatment,” Eur. J. Pharmacol., 851, 99–121 (2019), https://doi.org/10.1016/j.ejphar.2019.02.024.
J. A. Hamer, D. Testani, R. B. Mansur, et al., “Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression,” Exp. Neurol., 315, 1–8 (2019), https://doi.org/10.1016/j.expneurol.2019.01.016.
M. T. Treadway and D. H. Zald, “Parsing anhedonia: Translational models of reward-processing deficits in psychopathology,” Curr. Dir. Psychol. Sci., 22, No. 3, 244–249 (2013), https://doi.org/10.1177/0963721412474460.
B. Cao, J. Zhu, H. Zuckerman, et al., “Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 92, 109–117 (2019), https://doi.org/10.1016/j.pnpbp.2019.01.002.
A. S. Heller, T. Johnstone, A. J. Shackman, et al., “Reduced capacity to sustain positive emotion in major depression reflects diminished maintenance of fronto-striatal brain activation,” Proc. Natl. Acad. Sci. USA, 106, No. 52, 22445–22450 (2009), https://doi.org/10.1073/pnas.0910651106.
M. T. Treadway and D. A. Pizzagalli, “Imaging the pathophysiology of major depressive disorder – from localist models to circuit-based analysis,” Biol. Mood Anxiety Disord., 4, No. 1, 5 (2014), https://doi.org/10.1186/2045-5380-4-5.
C. B. Young, T. Chen, R. Nusslock, et al., “Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder,” Transl. Psychiatry, 6, No. 5, e810 (2016), https://doi.org/10.1038/tp.2016.80.
J. Keller, C. B. Young, E. Kelley, et al., “Trait anhedonia is associated with reduced reactivity and connectivity of mesolimbic and paralimbic reward pathways,” J. Psychiatr. Res., 47, No. 10, 1319–1328 (2013), https://doi.org/10.1016/j.jpsychires.2013.05.015.
V. Enneking, P. Krüssel, D. Zaremba, et al., “Social anhedonia in major depressive disorder: a symptom-specific neuroimaging approach,” Neuropsychopharmacology, 44, No. 5, 883–889 (2019), https://doi.org/10.1038/s41386-018-0283-6.
J. Wacker, D. G. Dillon, and D. A. Pizzagalli, “The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting, EEG, fMRI, and volumetric techniques,” Neuroimage, 46, No. 1, 327–337 (2009), https://doi.org/10.1016/j.neuroimage.2009.01.058.
M. Walter, A. Henning, S. Grimm, et al., “The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression,” Arch. Gen. Psychiatry, 66, No. 5, 478–486 (2009), https://doi.org/10.1001/archgenpsychiatry.2009.39.
G. W. Mies, I. Van den Berg, I. H. Franken, et al., “Neurophysiological correlates of anhedonia in feedback processing,” Front. Hum. Neurosci., 7, 96 (2013), https://doi.org/10.3389/fnhum.2013.00096.
N. S. Corral-Frías, Y. S. Nikolova, L. J. Michalski, et al., “Stress-related anhedonia is associated with ventral striatum reactivity to reward and transdiagnostic psychiatric symptomatology,” Psychol. Med., 45, No. 12, 2605–2617 (2015), https://doi.org/10.1017/S0033291715000525.
X. H. Yang, K. Tian, D. F. Wang, et al., “Anhedonia correlates with abnormal functional connectivity of the superior temporal gyrus and the caudate nucleus in patients with first-episode drug-naive major depressive disorder,” J. Affect. Disord., 218, 284–290 (2017), https://doi.org/10.1016/j.jad.2017.04.053.
M. S. Gaffrey, D. M. Barch, and R. Bogdan, “Amygdala reward reactivity mediates the association between preschool stress response and depression severity,” Biol. Psychiatry, 83, No. 2, 128–136 (2018), https://doi.org/10.1016/j.biopsych.2017.08.020.
R. P. Auerbach, A. Pisoni, E. Bondy, et al., “Neuroanatomical prediction of anhedonia in adolescents,” Neuropsychopharmacology, 42, No. 10, 2087–2095 (2017), https://doi.org/10.1038/npp.2017.28.
A. Stringaris, P. Vidal-Ribas Belil, E. Artiges, et al., “The brain's response to reward anticipation and depression in adolescence: dimensionality, specificity, and longitudinal predictions in a community-based sample,” Am. J. Psychiatry, 172, No. 12, 1215–1223 (2015), https://doi.org/10.1176/appi.ajp.2015.14101298.
L. Gong, C. He, H. Zhang, et al., “Disrupted reward and cognitive control networks contribute to anhedonia in depression,” J. Psychiatr. Res., 103, 61–68 (2018), https://doi.org/10.1016/j.jpsychires.2018.05.010.
G. Loas, E. Dalleau, H. Lecointe, and V. Yon, “Relationships between anhedonia, alexithymia, impulsivity, suicidal ideation, recent suicide attempt, C-reactive protein and serum lipid levels among 122 inpatients with mood or anxious disorders,” Psychiatry Res., 246, 296–302 (2016), https://doi.org/10.1016/j.psychres.2016.09.056.
N. Eisenberger, E. T. Berkman, T. K. Inagaki, et al., “Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward,” Biol. Psychiatry, 68, No. 8, 748–754 (2010), https://doi.org/10.1016/j.biopsych.2010.06.010.
Z. Pan, J. D. Rosenblat, W. Swardfager, and R. S. McIntyre, “Role of proinflammatory cytokines in dopaminergic system disturbances, implications for anhedonic features of MDD,” Curr. Pharm. Des., 23, No. 14, 2065–2072 (2017), https://doi.org/10.2174/1381612823666170111144340.
A. Caviedes, C. Lafourcade, C. Soto, and U. Wyneken, “BDNF/NF-κB signaling in the neurobiology of depression,” Curr. Pharm. Des., 23, No. 21, 3154–3163 (2017), https://doi.org/10.2174/1381612823666170111141915.
J. Carter and W. Swardfager, “Mood and metabolism: Anhedonia as a clinical target in Type 2 diabetes,” Psychoneuroendocrinology, 69, 123–132 (2016), https://doi.org/10.1016/j.psyneuen.2016.04.002.
N. G. Neznanov, G. E. Mazo, G. V. Rukavishnikov, and A. O. Kibitov, “Depression as a predictor of somatic disorders: pathological prerequisites and genetic risks,” Usp. Fiziol. Nauk., 48, No. 4, 29–39 (2017).
Y. Lee, M. Subramaniapillai, E. Brietzke, et al., “Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression,” Ther. Adv. Psychopharmacol., 8, No. 12, 337–348 (2018), https://doi.org/10.1177/2045125318791944.
A. Labbe, A. Bureau, I. Moreau, et al., “Symptom dimensions as alternative phenotypes to address genetic heterogeneity in schizophrenia and bipolar disorder,” Eur. J. Hum. Genet., 20, No. 11, 1182–1188 (2012), https://doi.org/10.1038/ejhg.2012.67.
D. Sieradzka, R. A. Power, D. Freeman, et al., “heritability of individual psychotic experiences captured by common genetic variants in a community sample of adolescents,” Behav. Genet., 45, No. 5, 493–502 (2015), https://doi.org/10.1007/s10519-015-9727-5.
R. Bogdan and D. A. Pizzagalli, “The heritability of hedonic capacity and perceived stress: a twin study evaluation of candidate depressive phenotypes,” Psychol. Med., 39, No. 2, 211–218 (2009), https://doi.org/10.1017/S0033291708003619.
D. A. Pizzagalli, A. L. Jahn, and J. P. O'Shea, “Toward an objective characterization of an anhedonic phenotype: a signal-detection approach,” Biol. Psychiatry, 57, No. 4, 319–327 (2005), https://doi.org/10.1016/j.biopsych.2004.11.026.
L. J. Michalski, C. H. Demers, and D. A. Baranger, “Perceived stress is associated with increased rostral middle frontal gyrus cortical thickness: a family-based and discordant-sibling investigation,” Genes Brain Behav., 16, No. 8, 781–789 (2017), https://doi.org/10.1111/gbb.12404.
P. A. Keedwell, R. Chapman, K. Christiansen, et al., “Cingulum white matter in young women at risk of depression: the effect of family history and anhedonia,” Biol. Psychiatry, 72, No. 4, 296–302 (2012), https://doi.org/10.1016/j.biopsych.2012.01.022.
M. Kovacs, L. M. Bylsma, I. Yaroslavsky, et al., “Positive affectivity is dampened in youths with histories of major depression and their never-depressed adolescent siblings,” Clin. Psychol. Sci., 4, No. 4, 661–674 (2016), https://doi.org/10.1177/2167702615607182.
L. T. Trias, H. E. Ebeling, V. Penninkilampi-Kerola, et al., “How long do the consequences of parental preference last: A study of twins from pregnancy to young adulthood,” Twin Res. Hum. Gen., 9, No. 2, 240–249 (2006), https://doi.org/10.1375/183242706776382509.
B. A. Makol and A. J. Polo, “parent-child endorsement discrepancies among youth at chronic-risk for depression,” J. Abnorm. Child Psychol., 46, No. 5, 1077–1088 (2018), https://doi.org/10.1007/s10802-017-0360-z.
O. Pain, F. Dudbridge, A. G. Cardno, et al., “Genome-wide analysis of adolescent psychotic-like experiences shows genetic overlap with psychiatric disorders,” Am J. Med. Genet. B Neuropsychiatr. Genet., 177, No. 4, 416–425 (2018), https://doi.org/10.1002/ajmg.b.32630.
H. Ren, C. Fabbri, R. Uher, et al., “Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP),” Transl. Psychiatry, 8, No. 1, 150 (2018), https://doi.org/10.1038/s41398-018-0198-3.
D. M. Howard, M. J. Adams, T. K. Clarke, et al., “Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions,” Nat. Neurosci., 22, No. 3, 343–352 (2019), https://doi.org/10.1038/s41593-018-0326-7.
R. Bogdan, Y. S. Nikolova, and D. A. Pizzagalli, “Neurogenetics of depression: a focus on reward processing and stress sensitivity,” Neurobiol. Dis., 52, 12–23 (2013), https://doi.org/10.1016/j.nbd.2012.05.007.
L. Keltikangas-Järvinen and J. Salo, “Dopamine and serotonin systems modify environmental effects on human behavior: a review,” Scand. J. Psychol., 50, No. 6, 574–582 (2009), https://doi.org/10.1111/j.1467-9450.2009.00785.x.
M. Mansari, B. P. Guiard, O. Chernoloz, et al., “Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder,” CNS Neurosci. Ther., 16, No. 3, e1–17 (2010), https://doi.org/10.1111/j.1755-5949.2010.00146.x.
M. Peciña, M. Sikora, E. T. Avery, et al., “Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response,” Eur Neuropsychopharmacol., 27, No. 10, 977–986 (2017), https://doi.org/10.1016/j.euroneuro.2017.08.427.
S. N. Light, L. A. Bieliauskas, and J. K. Zubieta, “'Top-down' mu-opioid system function in humans: mu-opioid receptors in ventrolateral prefrontal cortex mediate the relationship between hedonic tone and executive function in major depressive disorder,” J. Neuropsychiatry Clin. Neurosci., 29, No. 4, 357–364 (2017), https://doi.org/10.1176/appi.neuropsych.16090171.
L. Lalanne, G. Ayranci, B. L. Kieffer, and P. E. Lutz, “The kappa opioid receptor: from addiction to depression, and back,” Front. Psychiatry, 5, 170 (2014), https://doi.org/10.3389/fpsyt.2014.00170.
R. Bogdan, A. Agrawal, M. S. Gaffrey, et al., “Serotonin transporter-linked polymorphic region (5-HTTLPR) genotype and stressful life events interact to predict preschool-onset depression: a replication and developmental extension,” J. Child Psychol. Psychiatry, 55, No. 5, 448–457 (2014), https://doi.org/10.1111/jcpp.12142.
S. Wüst, I. S. Federenko, E. F. van Rossum, et al., “A psychobiological perspective on genetic determinants of hypothalamus-pituitary-adrenal axis activity,” Ann. N. Y. Acad. Sci., 1032, 52–62 (2004), https://doi.org/10.1196/annals.1314.005.
S. Wüst, E. F. Van Rossum, I. S. Federenko, et al., “Common polymorphisms in the glucocorticoid receptor gene are associated with adrenocortical responses to psychosocial stress,” J. Clin. Endocrinol. Metab., 89, No. 2, 565–573 (2004), https://doi.org/10.1210/jc.2003-031148.
I. S. Federenko, M. Nagamine, D. H. Hellhammer, et al., “The heritability of hypothalamus pituitary adrenal axis responses to psychosocial stress is context dependent,” J. Clin. Endocrinol. Metab., 89, No. 12, 6244–6250 (2004), https://doi.org/10.1210/jc.2004-0981.
C. R. DiIorio, C. E. Carey, L. J. Michalski, et al., “Hypothalamic-pituitary-adrenal axis genetic variation and early stress moderates amygdala function,” Psychoneuroendocrinology, 80, 170–178 (2017), https://doi.org/10.1016/j.psyneuen.2017.03.016.
A. Ching-López, J. Cervilla, M. Rivera, et al., “Epidemiological support for genetic variability at hypothalamic-pituitary-adrenal axis and serotonergic system as risk factors for major depression,” Neuropsychiatr. Dis. Treat., 11, 2743–2754 (2015), https://doi.org/10.2147/NDT.S90369.
Y. Nikolova, R. Bogdan, and D. A. Pizzagalli, “Perception of a naturalistic stressor interacts with 5-HTTLPR/rs25531 genotype and gender to impact reward responsiveness,” Neuropsychobiology, 65, No. 1, 45–54 (2012), https://doi.org/10.1159/000329105.
J. D. Kruschwitz, M. Walter, D. Varikuti, et al., “5-HTTLPR/rs25531 polymorphism and neuroticism are linked by resting state functional connectivity of amygdala and fusiform gyrus,” Brain Struct. Funct., 220, No. 4, 2373–2385 (2015), https://doi.org/10.1007/s00429-014-0782-0.
M. N. Servaas, L. Geerligs, J. A. Bastiaansen, et al., “Associations between genetic risk, functional brain network organization and neuroticism,” Brain Imaging Behav., 11, No. 6, 1581–1591 (2017), https://doi.org/10.1007/s11682-016-9626-2.
G. M. Hosang, C. Shiles, K. E. Tansey, et al., “Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis,” BMC Med., 12, 7 (2014), https://doi.org/10.1186/1741-7015-12-7.
M. M. Youssef, M. D. Underwood, Y. Y. Huang, et al., “Association of BDNF Val66Met polymorphism and brain BDNF levels with major depression and suicide,” Int. J. Neuropsychopharmacol., 21, No. 6, 528–538 (2018), https://doi.org/10.1093/ijnp/pyy008.
Y. K. Kim, B. J. Ham, and K. M. Han, “Interactive effects of genetic polymorphisms and childhood adversity on brain morphologic changes in depression,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 91, 4–13 (2019), https://doi.org/10.1016/j.pnpbp.2018.03.009.
K. M. Han, S. Choi, A. Kim, et al., “The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder,” Psychiatry Res. Neuroimag., 273, 25–34 (2018), https://doi.org/10.1016/j.pscychresns.2018.01.005.
T. M. Lancaster, E. A. Heerey, K. Mantripragada, and D. E. Linden, “Replication study implicates COMT val158met polymorphism as a modulator of probabilistic reward learning,” Genes Brain Behav., 14, No. 6, 486–492 (2015), https://doi.org/10.1111/gbb.12228.
A. J. Cleare and L. J. Rane, “Biological models of unipolar depression,” in: The Wiley-Blackwell Handbook of Mood Disorders, M. Power (ed.), Wiley-Blackwell; (2013), 2nd ed.
L. Pani, A. Porcella, and G. L. Gessa, “The role of stress in the pathophysiology of the dopaminergic system,” Mol. Psychiatry, 5, No. 1, 14–21 (2000), https://doi.org/10.1038/sj.mp.4000589.
H. R. Sim, T. Y. Choi, H. J. Lee, et al., “Role of dopamine D2 receptors in plasticity of stress-induced addictive behaviours,” Nat. Commun., 4, 1579 (2013), https://doi.org/10.1038/ncomms2598.
R. Ventura, S. Cabib, and S. Puglisi-Allegra, “Genetic susceptibility of mesocortical dopamine to stress determines liability to inhibition of mesoaccumbens dopamine and to behavioral 'despair' in a mouse model of depression,” Neuroscience, 115, No. 4, 999–1007 (2002), https://doi.org/10.1016/s0306-4522(02)00581-x.
E. J. Nestler and W. A. Carlezon, “The mesolimbic dopamine reward circuit in depression,” Biol. Psychiatry, 59, No. 12, 1151–1159 (2006), https://doi.org/10.1016/j.biopsych.2005.09.018.
R. Bogdan and B. J. Salmeron, “imaging genetics and genomics in psychiatry: A critical review of progress and potential,” Biol. Psychiatry, 82, No. 3, 165–175 (2017), https://doi.org/10.1016/j.biopsych.2016.12.030.
L. W. Hyde, R. Bogdan, and A. R. Hariri, “Understanding risk for psychopathology through imaging gene-environment interactions,” Trends Cogn. Sci., 15, No. 9, 417–427 (2011), https://doi.org/10.1016/j.tics.2011.07.001.
R. Bogdan, D. A. Baranger, and A. Agrawal, “Polygenic risk scores in clinical psychology: bridging genomic risk to individual differences,” Annu. Rev. Clin. Psychol., 14, 119–157 (2018), https://doi.org/10.1146/annurev-clinpsy-050817-084847.
S. S. Pathak, S. Maitra, S. Chakravarty, and A. Kumar, “Histone lysine demethylases of JMJD2 or KDM4 family are important epigenetic regulators in reward circuitry in the etiopathology of depression,” Neuropsychopharmacology, 42, No. 4, 854–863 (2017), https://doi.org/10.1038/npp.2016.231.
X. F. Shen, H. B. Yuan, G. Q. Wang, et al., “Role of DNA hypomethylation in lateral habenular nucleus in the development of depressive-like behavior in rats,” J. Affect. Disord., 252, 373–381 (2019), https://doi.org/10.1016/j.jad.2019.03.062.
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 3, Iss. 1, pp. 146–154, March, 2021.
About this article
Cite this article
Kibitov, A.O., Mazo, G.E. Anhedonia in Depression: Neurobiological and Genetic Aspects. Neurosci Behav Physi 52, 30–38 (2022). https://doi.org/10.1007/s11055-022-01204-8